| Name
|
Colivelin
|
| Sequence (Single letter abbreviations)
|
SALLRSIPAPAGASRLLLLTGEIDLP
|
| Sequence（Three letter abbreviations）
|
{Ser}{Ala}{Leu}{Leu}{Arg}{Ser}{Ile}{Pro}{Ala}{Pro}{Ala}{Gly}{Ala}{Ser}{Arg}{Leu}{Leu}{Leu}{Leu}{Thr}{Gly}{Glu}{Ile}{Asp}{Leu}{Pro}
|
| Basic description
|
Colivelin is a hybrid peptide synthesized to enhance the neuroprotective effects of humanin (HN). Colivelin is constructed as activity-dependent neurotrophic factor (ADNF) C-terminally fused to AGA-(C8R) HNG17, which is a potent HN derivative. Cell death induced by overexpressed familial Alzheimer's disease (FAD)-causative genes and beta-amyloid (1-43) can be completely suppressed by colivelin. Colivelin administered intraperitoneally suppresses memory impairment and may serve as a novel drug candidate to treat Alzheimer's disease.
|
| The molecular weight
|
2645.100
|
| Chemical formula
|
C119H206N32O35
|
| The purity
|
> 95%
|
| Storage conditions
|
Store at -20°C. Keep tightly closed. Store in a cool dry place
|
| Documents
|
|
| Figures
|
|
| Reference
|
Chiba, T. et al. J. Neurosci. 2005 Nov 2;25(44):10252-61.
|
Colivelin
